1999
Respiratorius was founded in 1999 to develop effective drugs to treat COPD and severe asthma, a therapeutic area still lacking in effective drugs.
“Arcede Pharma (publ) develops new patent-protected drug candidates with focus on chronic obstructive pulmonary disease (COPD) and severe asthma with the aim to improve quality of life, reduce suffering and prolong life expectancy”.
In the field of COPD and asthma, Arcede has developed compound series demonstrating bronchodilating effects in airway tissue from humans and animals, such as rat and dog. The project portfolio also contains a substance developed for use in PET imaging, aimed at facilitating the diagnosis of certain cardiovascular diseases.
Arcede Pharma was founded in 2022 as a result of the spin-out of the projects outside oncology being developed by Respiratorius AB, with focus on the respiratory disease projects.
Arcede Pharma is a separate company.
Arcede Pharma is a public company listed on the Spotlight Stock Market (formerly Aktietorget).
Business concept
Patent protected drug candidates based on new mode of actions showing promising results in preclinical studies.
Strategy
Arcede aims at being an attractive partner for academic research groups, biotech companies and global pharmaceutical companies with expertise positioned all along the drug development path – from academic research to finished product on the market.
Vision
Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.
Business model
Already at an early phase Arcede is interested in finding strategic partners who assume financial and operational responsibility from development to finished product. This type of partner will have financial resources, experience in large clinical studies and established contacts with regulatory authorities. These partners will also be responsible in the future for manufacturing, marketing and sales of the licensed drugs that may result from the development project.
A license agreement with a pharmaceutical company is expected to give Arcede income in the form of an initial payment followed by milestone payments, as well as royalties.
The timing of signing cooperation agreements with pharmaceutical companies will entail business decisions based on cost, risk, skill requirements and the value that would be added by completing additional steps in-house. Such cooperation agreements will ensure that the projects receive expertise and resources from pharmaceutical companies at an early stage. It is in the best interest of Arcede to to minimise time to market without compromising on safety, expertise or quality. –.
Organisation
Arcede operates based on a virtual model, without any employees, except the CEO. Resource and skill requirements vary during project development and specific expertise is and will be purchased as needed. This organisational model is totally focused on value-generating project development.
